Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Rating of “Hold” from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $376.30.

Several research analysts have recently weighed in on the company. Leerink Partnrs upgraded Medpace to a “hold” rating in a research note on Monday, March 24th. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price for the company. Finally, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Trust N.A. increased its stake in shares of Medpace by 34.6% in the 3rd quarter. Raymond James Trust N.A. now owns 754 shares of the company’s stock worth $252,000 after purchasing an additional 194 shares in the last quarter. Independent Advisor Alliance increased its position in Medpace by 16.7% in the third quarter. Independent Advisor Alliance now owns 941 shares of the company’s stock worth $314,000 after buying an additional 135 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Medpace by 42.6% in the third quarter. Bank of Montreal Can now owns 5,874 shares of the company’s stock worth $1,947,000 after buying an additional 1,755 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Medpace by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 21,469 shares of the company’s stock worth $7,166,000 after acquiring an additional 340 shares in the last quarter. Finally, FMR LLC increased its holdings in Medpace by 11.8% in the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after acquiring an additional 24,362 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

NASDAQ:MEDP opened at $297.73 on Friday. The firm has a market cap of $9.07 billion, a P/E ratio of 23.57, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace has a fifty-two week low of $289.01 and a fifty-two week high of $459.77. The firm has a 50-day simple moving average of $334.26 and a two-hundred day simple moving average of $338.52.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts predict that Medpace will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.